Study Summary
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
Want to learn more about this trial?
Request More InfoInterventions
MLM-CAR44.1 T-cells at day 0 Single intravenous infusionDRUG
Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Department of Haematooncology, Fakultni Nemocnice | Ostrava | Czech Republic | Czechia |
| IRCCS San Raffaele | Milan | Italy | |
| IRCCS Ospedale Pediatrico Bambino Gesù | Roma | Italy |